Moderna ( ($MRNA) ) has released its Q4 earnings. Here is a breakdown of the information Moderna presented to its investors. Moderna, Inc. is a ...

The U.S. Department of Agriculture has given a conditional approval to Zoetis to use its bird flu vaccine in poultry, the ...

Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

Moderna ( MRNA) reported mixed fourth quarter earnings, and full year 2024 earnings compared to Wall Street expectations Friday. Moderna's stock was down 4.5% in pre-market trading on the earnings ...

Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...

Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...

Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...

A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...